DTM 2017 (Diabetes Technology Meeting)

November 2-4, 2017; Bethesda, MD; Pre-preview – Draft

The 17th Annual Diabetes Technology Meeting will take place November 2-4, 2017 in Bethesda, Maryland, and boy is this agenda – an annual pulse on the state of diabetes tech – utterly PACKED. We’re thrilled to see that day #1 will begin with critical discussion on diabetes technology reimbursement in parallel with panels on insulin dosing and advances in insulin delivery (oral insulin, smart pens, etc.), though no actual payers seem to be in attendance. The latter workshop features a 15-minute presentation from Lilly’s Ms. Jennal Johnson on “pump delivery of U500 insulin” – could this be a sneak peek of U500 Omnipod data? Excitingly, there’s a whole panel on new end points for diabetes technology clinical trials – we’re glad to see continued discussion of outcomes beyond A1c (three of these speakers were active participants at the July 21 consensus meeting). The agenda also features artificial intelligence for decision support (we’re eager to hear from Verily’s Dr. Howard Zisser, TypeZero’s Dr. Boris Kovatchev, and Schneider Children’s Prof. Moshe Phillip on the matter) and includes the always-insightful pipeline updates from CGM companies Abbott, Roche, Medtronic, Dexcom, and Arkray. The meeting will showcase IP insulin delivery in three separate talks (two from Prof. Katharine Barnard and one from Harvard’s Dr. Frank Doyle). NIH’s Dr. Guillermo Arreaza-Rubin will present on the Artificial Pancreas Consortium, hopefully with updates on the progress of the major pivotal trials. The FDA is sending Drs. Stayce Beck and Courtney Lias to discuss FDA policies on direct-to-consumer advertising and glucose monitoring, respectively. This meeting will also not lack in “wow-factor,” as we’ll hear about the Novartis/Verily glucose-measuring contact lens (will we finally get an update?! A number of notables from the diabeterati have written this off), smart insulin from Dr. Zhen Gu (wow! – this will undoubtedly be the reason for many to attend), augmented reality in diabetes, hepatic-targeted insulin, and even continuous insulin monitoring. We’ll be providing you with a full preview in the coming weeks, but be sure to register and check out the complete agenda. Until then, refresh your memory with our previous coverage from 2016 (Day #1 and Days #2-3) and 2015, 2014, 2013, and 2012.


--by Maeve Serino, Brian Levine, Adam Brown, Kelly Close